SUV39H2 mediates H3K9me3 modification, promoting tumor progression (You et al., 2024), poor survival outcomes (Zheng et al., 2018), and chemoresistance (Vougiouklakis et al., 2018; Wang et al., 2019). Here, SUV39H2 is linked to neoplasm.